MaxxVision closes investment to launch new mammography product

TriMed Staff | | Health Imaging | Screening
MaxxVision LLC of Gainsville, Fla., a privately held developer of info-imaging systems, this week announced the closing of its second round of outside investment. The investment agreement signed with Emergent Growth Fund (Gainesville) includes $180,000 in funding for MaxxVision, providing working capital necessary to complete final design of its new iView FeatureFinder imaging device and bring the product to market in December.

iView is a lightweight, portable, handheld imaging device that enables physicians to perceive small, subtle features on mammography film images that may otherwise be overlooked.

TriMed Staff

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.